Drug Trial Radar · NCT05393193
POC HIV Testing and Early DTG Use for Infants
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Jul 4, 2022
Primary completion
Mar 16, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Harvard School of Public Health (HSPH)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Botswana Harvard AIDS Institute Partnership; Ragon Institute of MGH, MIT and Harvard; Botswana Ministry of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to explore the feasibility of implementing targeted birth HIV testing of high-risk neonates using facility-based point-of-care (POC) HIV diagnostics, and to improve the ability to implement the best standard-of-care treatment possible. Infants found to be HIV infected will be immediately offered enrollment into a dolutegravir (DTG) antiretroviral treatment study cohort (if maternal consent is granted) or referred for treatment at a government facility. Infants who enter the study treatment cohort will be prospectively followed through 96 weeks of age. ART will follow Botswana guidelines.
Conditions
- HIV
Interventions
Point-of-Care Cepheid Xpert HIV-1Diagnostic test
Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
DTG/ABC/3TCDrug
Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of high-risk HIV-exposed infants identified and testedTime frame: within 72 hours of life
- Median time to HIV diagnosis and treatment-dose ARTTime frame: 7 days
- The proportion of children with HIV-1 RNA <40 copies/mL at 12 weeks on ARTTime frame: 12 weeks on ART
- The proportion of children with successful DTG-based treatment through 96 weeks on ARTTime frame: 96 weeks on ART
- The proportion of infants with grade 3 or 4 adverse events/hospitalization/deathTime frame: 96 weeks on ART
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Botswana Harvard Health Partnership
Gaborone, Botswana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.